期刊文献+

玻璃体注射雷珠单抗治疗早产儿视网膜病变效果观察 被引量:1

Effects of Vitreous Injection of Ranibizumab on Retinopathy of Prematurity
下载PDF
导出
摘要 目的:探讨玻璃体注射雷珠单抗治疗早产儿视网膜病变(ROP)效果。方法:回顾性分析ROP患儿90例,依据治疗方式将给予视网膜光凝治疗患儿纳入对照组(n=43),行玻璃体注射雷珠单抗治疗患儿纳入观察组(n=47),比较2组患儿临床疗效。结果:观察组新生儿血管消退率(97.87%)高于对照组(74.42%),血管扩张迂曲好转率(96.81%)高于对照组(68.60%),视网膜增生发生率(1.06%)低于对照组(11.63%)(P<0.05);治疗后,观察组谷氨酸低于对照组[(75.30±21.78) mmol/L vs (89.87±19.56) mmol/L],血管内皮生长因子(VEGF)水平低于对照组[(352.44±46.30) ng/L vs (372.82±49.50) ng/L],胰岛素样生长因子-1(IGF-1)高于对照组[(40.65±9.33) ng/L vs (34.70±7.31) ng/L ](P<0.05);观察组治疗有效率(89.36%)高于对照组(65.12%)(P<0.05);观察组并发症发生率(3.19%)低于对照组(11.63%)(P<0.05)。结论:玻璃体注射雷珠单抗治疗ROP,可有效改善患儿血管造影表现和血清指标,效果显著,安全性较高。 Objective:To explore the effects of vitreous injection of ranibizumab in the treatment of retinopathy of prematurity (ROP). Methods: 90 patients with ROP diagnosed in our hospital were retrospectively analyzed. According to the treatment methods, children patients with retinal photocoagulation were included in control group (n=43), and children patients with intravitreal injection of ranibizumab were included in observation group (n=47). The clinical efficacy was compared between the two groups. Results: The effective rate of treatment in observation group was higher than that in control group (89.36% vs 65.12%)(P<0.05). The neonatal vascular regression rate in observation group was higher than that in control group (97.87% vs 74.42%), and the improvement rate of vasodilatation tortuosity was higher than that in control group (96.81% vs 68.60%), and the incidence rate of retinal hyperplasia was lower than that in control group (1.06% vs 11.63%)(P<0.05). The levels of glutamate and vascular endothelial growth factor (VEGF) in observation group were lower than those in control group, and insulin-like growth factor-1 (IGF-1) level was higher than that in control group (P<0.05). The incidence rate of complications in observation group was lower than that in control group (3.19% vs 11.63%)(P<0.05). Conclusion: Intravitreal injection of ranibizumab for the treatment of ROP can effectively improve the angiographic performance and serum index of children patients, and it has significant effects and high safety.
作者 陈新亚 白琼丹 李晶 付慧 Chen Xinya;Bai Qiongdan;Li Jing(Children's Hospital of Affiliated to Zhengzhou University)
出处 《长治医学院学报》 2019年第2期130-133,共4页 Journal of Changzhi Medical College
关键词 早产儿视网膜病变 玻璃体内注射 雷珠单抗 疗效 Retinopathy of prematurity intravitreal injection ranibizumab efficacy
  • 相关文献

参考文献9

二级参考文献43

  • 1罗先琼,柳国胜,赖日权,聂川,吴坤河,田野,夏明翰,康举龄.血管内皮生长因子及其受体在早产儿视网膜病大鼠模型中的表达和作用[J].中华儿科杂志,2004,42(7):511-515. 被引量:16
  • 2黎晓新.我国早产儿视网膜病变特点和筛查指南[J].中华眼底病杂志,2004,20(6):384-386. 被引量:140
  • 3高磊,赵秀芹,Wilson Yip,林顺潮.早产儿视网膜病变[J].中华眼底病杂志,2005,21(5):337-340. 被引量:30
  • 4黎晓新,陈宜.积极推动早产儿视网膜病变的防治[J].中华眼底病杂志,2008,24(1):1-4. 被引量:36
  • 5SINGER MA,AWH CC,SADDA S,FREEMAN WR,ANTOSZYK AN,WONG P,et al.HORIZON :An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related maculardengeration[J].Ophthalmology,2012,119(6):1175-1183.
  • 6CHUNG EJ,KIM JH,AHN HS,KOH HJ.Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity[J].Graefes Arch Clin Exp Ophtkalmol,2001,245(11):1727-1730.
  • 7QUIROZ-MERCADO H,MARTINEZ CASTELLANOS M,HER- NANDEZ-ROJAS M,SALAZAR-TERAN N,CHAN RV.Antian- giogenic therapy with intravitreal bevacizumab for retinopa- thy of prematurity[J].Retina,2008,28(3 Suppl):19-25.
  • 8TRAVASSOS A,TEIXEIRA S,FERREIRA P,REGADAS I,TRAVASSOS AS,ESPERANCINHA FE,et al,Intravitreal bev- acizumab in aggressive posterior retinopathy of prematurity[J].Ophthalmic Surg Lasers Imaging,2007,38(3):233-237.
  • 9INTERNATIONAL COMMITTEE FOR THE CLASSIFICATION OF RETINOPATHY OF PREMATURITY.The international classification of retinopathy of prematurity revisited[J].Arch Ophthalmol,2005,123(7):991-999.
  • 10MCNAMARA JA,TASMAN W,VANDER JF,BROWN GC.Di- ode laser photocoagulation for retinopathy of prematurity.Preliminary results[J].Arch Ophthalmol,1992,110(12):1714-1716.

共引文献96

同被引文献17

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部